...has partnered an anti-gonadotropin-releasing hormone (GnRH) vaccine in Phase II testing to treat prostate cancer. Immunovo B.V....
...series A round this summer. COMPANIES & INSTITUTIONS MENTIONED Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Immunovo B.V....

...Pepscan granted Immunovo an exclusive, worldwide license to develop and commercialize its vaccine portfolio for an...
...commercialize its vaccine portfolio for an undisclosed cash sum and a "significant minority" stake in Immunovo...
...mimicry technology for the generation of therapeutic peptides and mAbs. Further details were not disclosed. Immunovo B.V....